Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.

× No keyword cloud information.

25 in total

1. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Authors: Aaron N Hata; Alice T Shaw; Satoshi Yoda; Jessica J Lin; Michael S Lawrence; Benjamin J Burke; Luc Friboulet; Adam Langenbucher; Leila Dardaei; Kylie Prutisto-Chang; Ibiayi Dagogo-Jack; Sergei Timofeevski; Harper Hubbeling; Justin F Gainor; Lorin A Ferris; Amanda K Riley; Krystina E Kattermann; Daria Timonina; Rebecca S Heist; A John Iafrate; Cyril H Benes; Jochen K Lennerz; Mari Mino-Kenudson; Jeffrey A Engelman; Ted W Johnson
Journal: Cancer Discov Date: 2018-04-12 Impact factor: 39.397

Review 2. Resisting Resistance: Targeted Therapies in Lung Cancer.

Authors: Jessica J Lin; Alice T Shaw
Journal: Trends Cancer Date: 2016-07

Review 3. Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors: Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal: Cancer Discov Date: 2017-01-25 Impact factor: 39.397

Review 4. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors: Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal: Nat Rev Clin Oncol Date: 2022-05-09 Impact factor: 65.011

Review 5. Histologic transformation in lung cancer: when one door shuts, another opens.

Authors: Yuki Sato; Go Saito; Daichi Fujimoto
Journal: Ther Adv Med Oncol Date: 2022-10-14 Impact factor: 5.485

6. Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.

Authors: Benedito A Carneiro; Sahithi Pamarthy; Ami N Shah; Vinay Sagar; Kenji Unno; HuiYing Han; Ximing J Yang; Rubens B Costa; Rebecca J Nagy; Richard B Lanman; Timothy M Kuzel; Jeffrey S Ross; Laurie Gay; Julia A Elvin; Siraj M Ali; Massimo Cristofanilli; Young K Chae; Francis J Giles; Sarki A Abdulkadir
Journal: Clin Cancer Res Date: 2018-03-20 Impact factor: 12.531

Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.

1. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Review 2. Resisting Resistance: Targeted Therapies in Lung Cancer.

Review 3. Targeting ALK: Precision Medicine Takes on Drug Resistance.

Review 4. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Review 5. Histologic transformation in lung cancer: when one door shuts, another opens.

6. Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.

Review 7. The pharmacogenomics of drug resistance to protein kinase inhibitors.

Review 8. Personalized therapy for lung cancer: striking a moving target.

9. Histologic transformation of non-small-cell lung cancer in brain metastases.

Review 10. Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients.